Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer
- Author:
Fariz Nurwidya
;
Sita Andarini
;
Fumiyuki Takahashi
;
Elisna Syahruddin
;
Kazuhisa Takahashi
- Publication Type:Review
- Keywords:
IGF1R;
epithelial-mesenchymal transition;
cancer stem cells;
chemotherapy;
resistance;
clinical trials
- From:Malaysian Journal of Medical Sciences
2016;23(3):9-21
- CountryMalaysia
- Language:English
-
Abstract:
Insulin-like growth factor 1 receptor (IGF1R) has been intensively investigated in many
preclinical studies using cell lines and animal models, and the results have provided important
knowledge to help improve the understanding of cancer biology. IGF1R is highly expressed in
patients with lung cancer, and high levels of circulating insulin-like growth factor 1 (IGF1), the main
ligand for IGF1R, increases the risk of developing lung malignancy in the future. Several phase I
clinical trials have supported the potential use of an IGF1R-targeted strategy for cancer, including
lung cancer. However, the negative results from phase III studies need further attention, especially
in selecting patients with specific molecular signatures, who will gain benefits from IGF1R inhibitors
with minimal side effects. This review will discuss the basic concept of IGF1R in lung cancer biology,
such as epithelial-mesenchymal transition (EMT) induction and cancer stem cell (CSC) maintenance,
and also the clinical implications of IGF1R for lung cancer patients, such as prognostic value and
cancer therapy resistance.
- Full text:P020160518620131801409.pdf
